Medical News

RSS

Meda receives exclusive rights to distribute AML drug in Europe and Asia

Meda has in-licensed exclusive rights to Ceplene (histamine dihydrochloride) from EpiCept Corporation, a US-based biopharmaceutical company.

11 Jan 2010

KaloBios Pharmaceuticals, Sanofi Pasteur partner in development of KB001 biologic for Pa infections

KaloBios Pharmaceuticals, Inc. today announced an agreement with Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, for the development and commercialization of KB001, an investigational new biologic for the treatment or prevention of Pseudomonas aeruginosa (Pa) infections. Sanofi Pasteur will be responsible for the development and commercialization of KB001 and initially focus on hospital indications, including the prevention of Pa pneumonias in mechanically ventilated patients.

11 Jan 2010

EpiCept, Meda enter into exclusive commercialization agreement for Ceplene

EpiCept Corporation announced today that it has entered into an exclusive commercialization agreement for Ceplene® (histamine dihydrochloride) with Meda AB, a leading international specialty pharmaceutical company based in Stockholm. Ceplene is EpiCept’s novel therapy approved in the European Union with orphan drug status for the remission maintenance and prevention of relapse of patients with acute myeloid leukemia (AML) in first remission.

11 Jan 2010

Sanofi-aventis commences tender offer for Chattem through River Acquisition

Sanofi-aventis announced today the commencement of a tender offer through its wholly-owned subsidiary, River Acquisition Corp., for all outstanding shares of common stock of Chattem, Inc. for $93.50 per share, net to the seller in cash, without interest and less any required withholding taxes. The tender offer is being made pursuant to an Offer to Purchase, dated January 11, 2010, and in connection with the previously announced Agreement and Plan of Merger, dated December 20, 2009, among sanofi-aventis, River Acquisition Corp. and Chattem, Inc.

11 Jan 2010

Bryant Ranch Prepack tracks medications from its manufacture to the patient with E Pedigree

“More and more physicians are realizing that prescriptions that leave the office are like money walking out of the door,” said Fred Ganjian, Vice President of Sales and Marketing for Bryant Ranch Prepack, a leading supplier of prepackaged physician-dispensed prescription programs. “In this day of continuing pressure on physicians to cover their costs, physician-dispensed prescriptions have become increasingly important to a physician’s bottom line,” he added.

11 Jan 2010

WuXi AppTec enters into partnership with QIAGEN

WuXi AppTec Inc. today announced that it has entered into a partnership with QIAGEN to provide an integrated single solution for molecular biomarker development, validation and personalized healthcare targets to their respective client bases.

From QIAGEN Manchester Limited 11 Jan 2010

Variations in SNPs involved in modulating electrical impulse that govern working of heart discovered

Scientists at deCODE genetics today report the discovery of seven novel and common single-letter variations in the sequence of the human genome (SNPs) that are involved in modulating the electrical impulses that govern the working of the heart.

11 Jan 2010

Vertex Pharmaceuticals plans proof-of-concept clinical trials in RA and epilepsy

Vertex Pharmaceuticals Incorporated today provided an update on key 2010 business priorities in conjunction with the 28th Annual J.P. Morgan Healthcare Conference in San Francisco. The company also discussed recent progress in its lead development programs in hepatitis C virus (HCV) infection and cystic fibrosis (CF) and outlined proof-of-concept clinical trials planned in other serious diseases for 2010.

11 Jan 2010

BIDMC scientists identify new pathway to address the problem of photophobia during migraines

Ask anyone who suffers from migraine headaches what they do when they're having an attack, and you're likely to hear "go into a dark room." And although it's long been known that light makes migraines worse, the reason why has been unclear.

11 Jan 2010

Common brain tumour in children can arise from stem cells

New research from scientists at Queen Mary, University of London shows how the most common type of children's brain cancer can arise from stem cells.

11 Jan 2010

Researchers identify treatment to reduce health problems associated with enzyme defect

An experimental compound repaired a defective alcohol metabolism enzyme that affects an estimated 1 billion people worldwide, according to research supported by the National Institute on Alcohol Abuse and Alcoholism (NIAAA).

10 Jan 2010

New breakthroughs in AS genome-wide association study

Work done in part by researchers at The University of Texas Health Science Center at Houston has led to the discovery of two new genes that are implicated in ankylosing spondylitis (AS), an inflammatory and potentially disabling disease. In addition, the international research team pinpointed two areas along stretches of DNA that play an important role in regulating gene activity associated with the arthritic condition.

10 Jan 2010

Autism spectrum disorders result from miswiring of connections in developing brain

Studying a rare disorder known as tuberous sclerosis complex (TSC), researchers at Children's Hospital Boston add to a growing body of evidence suggesting that autism spectrum disorders, which affect 25 to 50 percent of TSC patients, result from a miswiring of connections in the developing brain, leading to improper information flow.

10 Jan 2010

Highmark joins with CDC to promote National Influenza Vaccination Week

Beginning Sunday, Jan. 10 and continuing through the week, Highmark Inc. will join with the Centers for Disease Control (CDC) to promote National Influenza Vaccination Week.

10 Jan 2010

Research into "chemical chaperone" may lead to new treatments for heart attacks

Researchers at the Indiana University and Stanford University schools of medicine have determined how a "chemical chaperone" does its job in the body, which could lead to a new class of drugs to help reduce the muscle damage caused by heart attacks.

10 Jan 2010

AMAG Pharmaceuticals provides update on the commercial launch of Feraheme Injection

AMAG Pharmaceuticals, Inc. today provided an update on the commercial launch of Feraheme® (ferumoxytol) Injection for intravenous (IV) use, including preliminary fourth quarter 2009 Feraheme net product revenues estimates, as well as an update on the Company’s international and label expansion efforts.

10 Jan 2010

Medical News

Meda receives exclusive rights to distribute AML drug in Europe and Asia

KaloBios Pharmaceuticals, Sanofi Pasteur partner in development of KB001 biologic for Pa infections

EpiCept, Meda enter into exclusive commercialization agreement for Ceplene

Sanofi-aventis commences tender offer for Chattem through River Acquisition

Bryant Ranch Prepack tracks medications from its manufacture to the patient with E Pedigree

WuXi AppTec enters into partnership with QIAGEN

Variations in SNPs involved in modulating electrical impulse that govern working of heart discovered

Vertex Pharmaceuticals plans proof-of-concept clinical trials in RA and epilepsy

BIDMC scientists identify new pathway to address the problem of photophobia during migraines

Common brain tumour in children can arise from stem cells

Researchers identify treatment to reduce health problems associated with enzyme defect

New breakthroughs in AS genome-wide association study

Autism spectrum disorders result from miswiring of connections in developing brain

Highmark joins with CDC to promote National Influenza Vaccination Week

Research into "chemical chaperone" may lead to new treatments for heart attacks

AMAG Pharmaceuticals provides update on the commercial launch of Feraheme Injection

Second-quarter fiscal 2010 results announced by Allscripts-Misys Healthcare Solutions

Quidel to acquire Diagnostic Hybrids for $130M

Experts from Johns Hopkins Medicine comment on healthcare reform

Thirteen percent of poison exposure calls related to painkillers

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Latest News